05-Jan-2021 - Charles River Laboratories, Inc.

Charles River Laboratories Acquires Distributed Bio

Charles River Laboratories International, Inc. announced that it acquired of Distributed Bio, Inc. on December 31, 2020. The acquisition marks the culmination of an exclusive partnership between these companies that was initiated in October 2018.

Based in South San Francisco, California, Distributed Bio is a next-generation antibody discovery company. Distributed Bio’s SuperHuman™ antibody libraries and integrated antibody optimization technologies help to enhance the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. Distributed Bio’s libraries are computationally optimized for both sequence diversity and immuno-engineering fitness through the analysis of thousands of human antibody repertoires and all known monoclonal therapeutics in clinical trials, which can generate many unique binders against every antigen tested. This large molecule discovery platform improves the chance of successful hit finding, reduces optimization requirements, and thereby expedites the antibody discovery process by several months. Distributed Bio’s computational immunology expertise also enables optimization of existing client antibodies generated through more traditional platforms, such as hybridoma or traditional phage display.

The acquisition of Distributed Bio expands Charles River’s scientific capabilities with an innovative, large-molecule discovery platform. The transaction combines Distributed Bio’s antibody libraries and immuno-engineering platform with Charles River’s extensive drug discovery and non-clinical development expertise to create an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “The addition of Distributed Bio’s next-generation antibody discovery capabilities further enhances Charles River’s unique ability to serve as a single-source partner to support our clients’ early-stage research. Our successful partnership has already generated significant client interest and we believe our broader platform will continue to attract new discovery business opportunities. Distributed Bio’s large-molecule discovery platform fills a gap in our portfolio and expands our early discovery expertise in a complex drug modality that few CROs can successfully offer. With its focus on speed and design efficiency, we believe the acquisition of Distributed Bio will enable us to build upon the more than 80 novel small molecule candidates that we have discovered for our clients and meet our goal of eliminating an additional year from our clients’ early-stage development timelines. We are pleased to welcome Distributed Bio to the Charles River family.”

“We believe our clients’ willingness to outsource more of their discovery programs will be predicated on our ability to continue to add innovative capabilities to meet our clients’ critical research needs, which we are accomplishing through strategic acquisitions and our partnership strategy. Distributed Bio is an example of our selective technology investments potentially becoming acquisitions after working with the target company for a meaningful period of time to provide its services to our clients. By adding innovative capabilities like large molecule discovery, we are enabling our clients to remain with one scientific partner from target identification through IND filing, and solidifying our position as the leading, early-stage contract research organization,” Mr. Foster concluded.

Financial and Transaction Details

The purchase price was $83 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $21 million based on future performance. The proposed acquisition and associated fees have been financed through Charles River’s existing revolving credit facility and cash.

Distributed Bio’s estimated annual revenue in 2020 was approximately $15 million. The transaction is not expected to have a material impact on Charles River’s GAAP or non-GAAP financial results in 2021. Distributed Bio will become part of the Company’s Discovery and Safety Assessment segment.

Facts, background information, dossiers
More about Charles River
  • News

    Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities

    Charles River Laboratories International, Inc. announced that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. The pur ... more

    Charles River to Acquire HemaCare

    Charles River Laboratories International, Inc. and HemaCare Corporation announced a definitive agreement for Charles River to acquire HemaCare for approximately $380 million in cash. HemaCare is a leader in the production of human-derived cellular products for the cell therapy market. The b ... more

    Charles River Laboratories to acquire French CRO

    Charles River Laboratories International, Inc. announced that it has signed a binding offer to acquire Citoxlab for €448 million in cash (or approximately $510 million based on current exchange rates), subject to customary closing adjustments. The proposed transaction is expected to close i ... more

  • Companies

    Charles River Endotoxin Microbial Detection Europe SAS

    Charles River is the world's leading supplier of endotoxin detection products. As a global provider of rapid microbiological product solutions, our goal is to provide superior product quality and consistency to the scientific community. more

    Charles River Laboratories, Inc.

    From our headquarters near Boston, MA, Charles River Laboratories' 7,500 employees serve clients as global providers of solutions that advance the drug discovery and development process. Our leading-edge products and services enable our clients to bring drugs to market faster and more eff ... more

    Charles River Laboratories Clinical Services GmbH

    From our headquarters near Boston, MA, Charles River Laboratories' 7,500 employees serve clients as global providers of solutions that advance the drug discovery and development process. Our leading-edge products and services enable our clients to bring drugs to market faster and more eff ... more